Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

Clinical trial NCT04676360 · TERMINATED

Trial details

NCT number: NCT04676360
Sponsor: Jacob Soumerai, MD
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsed Plasmablastic Lymphoma Refractory Plasmablastic Lymphoma Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma

Start date: 2021-07-01
Primary completion: 2023-11-27
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.